Global Decentralized Clinical Trials Market Size Likely to Grow at a CAGR of 14.5% By 2035

The market size of the global decentralized clinical trials will be estimated at USD 9.9 billion in 2025 and is expected to grow between USD 11.3 billion in 2026 and about USD 38.3 billion by 2035 with a current CAGR of 14.5% during the period of 2026 to 2035.

Decentralized Clinical Trials Market Revenue and Trends

Decentralized clinical trials are a modern approach to clinical research where the use of digital technologies and remote services allows trial activities to be performed outside the traditional research sites. For instance, in a decentralized trial, the whole range of the processes from patient recruitment through informed consent, data collection, monitoring, and even follow-up visits would be done through, e.g., telemedicine, mHealth apps, wearables, ePRO, and cloud data storage. Such a method offers the patients the luxury of taking part in the study from the comfort of their homes or local hospitals, thereby lowering the burden of traveling and also improving access to the studies. With the technological and patient-focused paradigms taking over, decentralized clinical trials are said to be the future, as they offer the benefits of getting more patients into the study, keeping them there, and getting their data while at the same time being compliant with the regulations and preserving the integrity of the study.

What are the Factors That Have a Significant Contribution to the Growth of the Decentralized Clinical Trials Market?

Digital health tools have been the predominant factor for the DCT industry's growth through the provision of remote, real-time, and patient-centered trial execution. Such technologies include wearable devices, mobile health apps, electronic patient-reported outcomes (ePRO), telemedicine platforms, and electronic consent (eConsent), which all facilitate ongoing data collection and patient interactions in a virtual setting beyond the confines of traditional trial sites. Furthermore, it is these tools that have played a significant role in improving the process of patient recruitment, engagement, and retention while at the same time cutting down on the operational costs and study duration significantly. In addition, the digital health solutions have not only improved the accuracy of the data, monitoring, and compliance with the rules and regulations, but also made the decentralized and hybrid trial models more efficient and scalable, thus leading to the overall acceleration of the DCT industry growth.

Additionally, the ecosystem growth with the increasing involvement of CROs, platform vendors, and system integrators is one of the key factors that is accelerating the decentralized clinical trials market, as it makes the process of adoption easier and less risky for the sponsors. In a parallel scenario, the contract research organizations are catering to the demand with end-to-end decentralized and hybrid trial services. Also, the specialized platform vendors are contributing by providing integrated solutions for eConsent, telemedicine, remote monitoring, and data analytics. The role of system integrators is to increase the interoperability by linking together the digital tools, clinical systems, and regulatory workflows into a single trial environment. Consequently, this ecosystem is very mature and collaborative; thus, it has the potential to lower the barriers to implementation, improve scalability, and increase sponsor confidence, which eventually will lead to more extensive adoption and continuous revenue growth in the DCT market.

Segment Insight

By Therapeutic Application

The oncology segment held the largest market share of over 45% in 2025. The ascent in demand is linked to the gradual integration of decentralized and hybrid components in oncology research trials. In the past, oncology trials had to face very slow patient recruitment, high dropout rates, and very frequent visits to sites with complex monitoring that took a long time and increased costs. Decentralized methods help to a great extent. These methods consisting of remote patient engagement, telemedicine consultations, continuous monitoring through wearables, and ePRO allow participating patients at home or nearby clinics to avoid the hassle of traveling regularly to the specialized oncology center.

The number of potential patients is thus greatly increased, which is particularly crucial for rare tumors or when the patients are spread over a large area. Therefore, the time needed for recruiting is proportionately reduced as well as the number of dropouts before the end of the trial. Besides that, one factor simplifying the complexity of oncology studies has been the use of hybrid designs where critical interventions still occur at the clinical site while routine clinical assessments and follow-ups are done through remote means.

By End User

The pharmaceutical & biotech sponsors held the largest market share of more than 55% in 2025. As these organizations are progressively incorporating decentralized and hybrid trial methodologies into their clinical development practices. Pharmaceutical and biotech companies are under pressure to minimize drug development times, to recruit and retain patients effectively, and to keep the R&D costs from getting out of control, all of which decentralized approaches can help with. The use of remote monitoring technologies, telemedicine visits, electronic consent, and mobile health platforms allows sponsors to not only increase their geographic reach but also make it easier for patients to participate and therefore shorten the time it takes to enrol—especially with hard-to-reach or rare disease populations.

Regional Insights

North America held the highest market share in 2025. The main contributors to this growth are basically the best healthcare infrastructure in the world, a huge investment in research and development, and a strong ecosystem of pharmaceutical, biotech, and CROs that are the first to embrace the use of digital and remote trial technologies. The U.S. and Canadian regulatory and reimbursement systems, by facilitating telemedicine and virtual trial components, help the sponsors to relax when deciding to integrate decentralized and hybrid trial aspects.

Besides, the Asia Pacific market has the highest rate of growth in the decentralized clinical trials market. Asia-Pacific is not only able to offer but also has the advantage of being the most affordable region for conducting clinical trials relative to the West which is why it is very much in demand by global sponsors for the purpose of trial budget optimization without sacrificing quality and compliance with regulations. The combination of such demographic advantages, technological readiness, investment flows and cost efficiencies has been the major factor contributing to the rapid expansion of decentralized clinical trials in the Asia-Pacific region.

Report Scope

Recent Developments

• In October 2024, Medable Inc., the foremost provider of clinical development technology, declared a partnership with Google Cloud that would result in bringing Medable’s Digital and Decentralized Clinical Trial Platform to Google Cloud Marketplace. The customers will gain access to the latest Google Cloud infrastructure and AI capabilities, perfectly intertwined with Medable’s platform, particularly the recently introduced Studio, a one-of-a-kind SaaS solution that grants pharma companies control and transparency over clinical trial design, implementation, and management. Medable’s strategic partnership with Google Cloud grants life sciences firms the opportunity to quicken up the clinical development process while simultaneously enjoying the advantages of infrastructure and finance. (Source: https://www.medable.com/newsroom/medable-joins-forces-with-google-cloud-to-deliver-digital-clinical-trials-technology-on-google-cloud-marketplace)

List of the prominent players in the Decentralized Clinical Trials Market:

• ICON plc

• Thermo Fisher Scientific (Clinical Research Group)

• IQVIA Inc.

• Dassault Systèmes

• Clario

• ProPharma

• Curebase

• Oracle (Health Sciences)

• Veristat

• Everest Global

• Curavit

• Obvio Health

• Florence Healthcare

• Advarra

• Labcorp Drug Development

• Parexe

• Syneos Health

• Others

The Decentralized Clinical Trials Market is segmented as follows:

By Study Design

• Interventional

• Observational

• Expanded Access

By Component

• Cloud-Based Platforms

• Web-Based Platforms

• Hybrid/App-Centric Platforms

By Therapeutic Application

• Oncology

• Cardiology

• Neurology

• Respiratory

• Others

By End User

• Pharmaceutical & Biotech Sponsors

• Medical-Device Manufacturers

• Contract Research Organizations (CROs)

• Academic & Research Institutes

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America